ES2052012T3 - Naftoquinonas para el tratamiento y profilaxis de infecciones por pneumocystis carinii. - Google Patents

Naftoquinonas para el tratamiento y profilaxis de infecciones por pneumocystis carinii.

Info

Publication number
ES2052012T3
ES2052012T3 ES89308268T ES89308268T ES2052012T3 ES 2052012 T3 ES2052012 T3 ES 2052012T3 ES 89308268 T ES89308268 T ES 89308268T ES 89308268 T ES89308268 T ES 89308268T ES 2052012 T3 ES2052012 T3 ES 2052012T3
Authority
ES
Spain
Prior art keywords
group
prophylaxis
treatment
carinii infections
pneumocystis carinii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89308268T
Other languages
English (en)
Inventor
Victoria Susan Latter
Winston Edward Gutteridge
Alan Thomas Hudson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888819477A external-priority patent/GB8819477D0/en
Priority claimed from GB888819480A external-priority patent/GB8819480D0/en
Priority claimed from GB888819478A external-priority patent/GB8819478D0/en
Priority claimed from GB888819479A external-priority patent/GB8819479D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2052012T3 publication Critical patent/ES2052012T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/12—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/30—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C46/00—Preparation of quinones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/24—Quinones containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/013—Esters of alcohols having the esterified hydroxy group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

EL PRESENTE INVENTO SE REFIERE AL USO DE CONOCIDAD Y NUEVAS NAFTOQUINONAS EN EL TRATAMIENTO Y PROFILAXIS DE INFECCIONES "PNEUMOCYSTIS CARINII", Y PARA LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO Y PROFILAXIS DE "PNEUMOCYSTIS CARINII", TAMBIEN SE PRESENTAN NUEVAS FORMULACIONES CONTENIENDO DICHOS COMPUESTOS Y NUEVAS NAFTOQUINONAS DE FORMULA (VI) EN DONDE R11 Y R12 CADA UNA REPRESENTAN =0 Y LA LINEA PUNTEADA REPRESENTA UN DOBLE ENLACE ENTRE LAS POSICIONES 2 Y 3 DEL ANILLO DE QUINONA, EN CUYO CASO R13 REPRESENTA UN GRUPO -OCOR5; UN GRUPO OR6 O SR6; O UN GRUPO NR7R8; O LA LINEA PUNTEADA REPRESENTA ENLACES DOBLES EN LA POSICIONES 1,2 Y 3, 4 DEL ANILLO QUINOL Y R11, R12 Y R13 REPRESENTAN CADA UNO UN GRUPO -OCOR14, EN DONDE R14 REPRESENTA UN GRUPO ALKIL C1 - C10 OPCIONALMENTE SUSTITUIDO.
ES89308268T 1988-08-16 1989-08-15 Naftoquinonas para el tratamiento y profilaxis de infecciones por pneumocystis carinii. Expired - Lifetime ES2052012T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB888819477A GB8819477D0 (en) 1988-08-16 1988-08-16 Medicaments
GB888819480A GB8819480D0 (en) 1988-08-16 1988-08-16 Medicaments
GB888819478A GB8819478D0 (en) 1988-08-16 1988-08-16 Medicaments
GB888819479A GB8819479D0 (en) 1988-08-16 1988-08-16 Medicaments

Publications (1)

Publication Number Publication Date
ES2052012T3 true ES2052012T3 (es) 1994-07-01

Family

ID=27450160

Family Applications (2)

Application Number Title Priority Date Filing Date
ES93113704T Expired - Lifetime ES2130199T3 (es) 1988-08-16 1989-08-15 Nuevas naftoquinonas y su uso como medicamento.
ES89308268T Expired - Lifetime ES2052012T3 (es) 1988-08-16 1989-08-15 Naftoquinonas para el tratamiento y profilaxis de infecciones por pneumocystis carinii.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES93113704T Expired - Lifetime ES2130199T3 (es) 1988-08-16 1989-08-15 Nuevas naftoquinonas y su uso como medicamento.

Country Status (20)

Country Link
EP (2) EP0362996B1 (es)
JP (1) JP2804302B2 (es)
AT (1) ATE178311T1 (es)
AU (1) AU633836B2 (es)
CA (1) CA1329621C (es)
CY (1) CY1863A (es)
DE (2) DE68914930T2 (es)
DK (1) DK175787B1 (es)
ES (2) ES2130199T3 (es)
FI (1) FI893835A (es)
HK (1) HK103395A (es)
HU (1) HU208624B (es)
IE (1) IE65715B1 (es)
IL (1) IL91308A (es)
LV (1) LV11273B (es)
MX (1) MX9202995A (es)
NZ (1) NZ230313A (es)
PT (2) PT91456B (es)
SA (1) SA95160138B1 (es)
SG (1) SG23618G (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0567162A1 (en) * 1989-09-22 1993-10-27 The Wellcome Foundation Limited Medicaments for the treatment of toxoplasmosis
GB8921516D0 (en) * 1989-09-22 1989-11-08 Wellcome Found Medicaments
GB9103075D0 (en) * 1991-02-13 1991-03-27 Washington Odur Ayuko Trinitrobenzene derivatives and their therapeutic use
GB9121316D0 (en) * 1991-10-09 1991-11-20 Wellcome Found Heterocyclic compounds
GB9126874D0 (en) * 1991-12-18 1992-02-19 Wellcome Found Medicaments
GB9207517D0 (en) * 1992-04-06 1992-05-20 Wellcome Found Heterocyclic compounds
GB9216859D0 (en) * 1992-08-07 1992-09-23 Wellcome Found Medicaments
GB9224739D0 (en) 1992-11-26 1993-01-13 Wellcome Found Medicaments
GB9226905D0 (en) * 1992-12-24 1993-02-17 Wellcome Found Pharmaceutical preparation
AU3705695A (en) * 1994-10-26 1996-05-23 Wellcome Foundation Limited, The Pharmaceutical composition comprising atovaquone
GB9613309D0 (en) * 1996-06-25 1996-08-28 Univ Sheffield Quinone bacterial inhibitors
EP1779892A4 (en) * 2004-07-30 2010-05-19 Japan Health Science Found AGAINST PROTOZOON
WO2009007991A2 (en) 2007-04-19 2009-01-15 Ipca Laboratories Limited A new process for preparation of atovaquone and novel intermediates thereof
ITMI20070941A1 (it) * 2007-05-09 2008-11-10 Chimico Internazi0Nale S P A L Procedimento per la preparazione di naftochinoni trans2,3-disostituiti
US9169232B2 (en) * 2011-09-16 2015-10-27 Alkem Laboratories Limited 3-(5-methyl-2-oxo-l, 3-dioxol-4-yl) methyloxy-2-trans-[(4-chloro phenyl) cyclohexyl][1,4]naphthaquinone-atovaquone prodrug
CA3028392A1 (en) * 2016-06-20 2017-12-28 The Scripps Research Institute Antimalarial compositions and uses thereof
WO2022144920A1 (en) * 2020-12-30 2022-07-07 Ipca Laboratories Limited Atovaquone prodrugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1553424A (en) * 1976-02-10 1979-09-26 Wellcome Found Method of treating protozal diseases
US4485117A (en) * 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
GB8310141D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Naphthoquinone derivatives
GB8310140D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Antiprotozoal agents
GB8500292D0 (en) * 1985-01-07 1985-02-13 Wellcome Found Treatment of babesiosis
DE3801743A1 (de) * 1987-07-03 1989-01-19 Bayer Ag Schaedlingsbekaempfungsmittel auf basis von substituierten 1,4-naphthochinonen und neue substituierte 1,4-naphthochinone

Also Published As

Publication number Publication date
DE68914930T2 (de) 1994-08-18
DE68914930D1 (de) 1994-06-01
AU3994889A (en) 1990-02-22
CA1329621C (en) 1994-05-17
ATE178311T1 (de) 1999-04-15
PT91456B (pt) 1996-06-28
AU633836B2 (en) 1993-02-11
DE68928964D1 (de) 1999-05-06
LV11273B (en) 1996-10-20
EP0580185B1 (en) 1999-03-31
DK399989D0 (da) 1989-08-15
ES2130199T3 (es) 1999-07-01
MX9202995A (es) 1992-07-01
DK175787B1 (da) 2005-02-21
JP2804302B2 (ja) 1998-09-24
DK399989A (da) 1990-02-17
PT91456A (pt) 1990-03-08
HUT57041A (en) 1991-11-28
CY1863A (en) 1996-04-05
IE892616L (en) 1990-02-16
IL91308A (en) 1994-07-31
DE68928964T2 (de) 1999-07-29
EP0362996B1 (en) 1994-04-27
FI893835A0 (fi) 1989-08-15
NZ230313A (en) 1992-07-28
SA95160138B1 (ar) 2006-03-15
LV11273A (lv) 1996-06-20
FI893835A (fi) 1990-02-17
PT101734A (pt) 1996-01-31
SG23618G (en) 1995-09-18
HU911004D0 (en) 1991-10-28
EP0362996A3 (en) 1992-04-15
EP0362996A2 (en) 1990-04-11
JPH0291037A (ja) 1990-03-30
HU208624B (en) 1993-12-28
HK103395A (en) 1995-07-07
PT101734B (pt) 1997-08-29
IL91308A0 (en) 1990-03-19
IE65715B1 (en) 1995-11-15
EP0580185A1 (en) 1994-01-26

Similar Documents

Publication Publication Date Title
ES2052012T3 (es) Naftoquinonas para el tratamiento y profilaxis de infecciones por pneumocystis carinii.
MX9306079A (es) Agente inmunopotenciador y sus sales fisiologicamente aceptables.
ATE90197T1 (de) Orale praeparate.
PT87745A (pt) Process for the preparation of pharmaceutical compounds containing cyclosporins
DE68911742D1 (de) Substituierte flavonoide Verbindungen, ihre Salze, ihre Herstellung und die enthaltende Arnzeizusammensetzungen.
NO303783B1 (no) Substituerte aminofosfonatderivater og farmas°ytiske preparater derav
IT1212141B (it) Composizioni farmaceutiche per la prevenzione e terapia della calcolosi delle vie biliari e della dispepsia biliare.
SE8600658D0 (sv) Novel composition of matter
DK576887D0 (da) Farmaceutiske midler
MY105807A (en) Medicaments
ITMI913461A0 (it) Composizioni terapeutiche adatte per la somministrazione rettale contenenti come principio attivo uno o piu' tioesteri del glutatione
KR900003100A (ko) 나프토퀴논

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 362996

Country of ref document: ES